Literature DB >> 11091175

Biological activity of endogenous atrial natriuretic peptide during cardiopulmonary bypass.

N Hayashida1, S Chihara, H Kashikie, E Tayama, S Yokose, K Akasu, S Aoyagi.   

Abstract

To evaluate the effect of cardiopulmonary bypass (CPB) on atrial natriuretic peptide (ANP) biological activity in patients undergoing cardiac operations, we conducted a prospective study. Ten patients undergoing mitral valve surgery were enrolled. Plasma levels of ANP and cyclic guanosine monophosphate (cGMP), hemodynamic variables, and renal function parameters were assessed perioperatively. The molar ratio of cGMP to ANP (as a marker for ANP biological activity) decreased significantly (p < 0.05) during CPB despite similar plasma ANP levels. The ratio correlated inversely with the duration of CPB (r = -0.85, p = 0.002). The ratio also correlated with fractional sodium excretion (r = 0.65, p = 0.04) and correlated inversely with pulmonary vascular resistance (r = -0.79, p = 0.009) and atrial filling pressure (r = -0.84, p= 0.003) postoperatively. CPB decreased the molar ratio of cGMP to ANP, which may represent ANP biological activity, such as vasodilation and natriuresis. The phenomenon may contribute to water-sodium retention and pulmonary hypertension after cardiac surgery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11091175     DOI: 10.1046/j.1525-1594.2000.06514-3.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  2 in total

1.  The role of brain natriuretic peptide in the prediction of cardiac performance in coronary artery bypass grafting.

Authors:  Osman Saribulbul; Ilker Alat; Senol Coskun; Anil Z Apaydin; Tahir Yagdi; Mefkure Kiliccioglu; Emin Alp Alayunt
Journal:  Tex Heart Inst J       Date:  2003

2.  Alterations in the natriuretic hormone system related to cardiopulmonary bypass in infants with congestive heart failure.

Authors:  J M Costello; C L Backer; P A Checchia; C Mavroudis; R G Seipelt; D M Goodman
Journal:  Pediatr Cardiol       Date:  2004 Jul-Aug       Impact factor: 1.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.